Prenetics Global (PRE) investor relations material

Company overview and business model

• Focuses on consumer health and longevity, with flagship brand IM8 offering premium, science-backed daily nutrition products and CircleDNA providing comprehensive genetic testing services.

• IM8 operates as a digitally native, subscription-first, direct-to-consumer brand, achieving $120 million in annualized recurring revenue within twelve months of launch and shipping to over 30 countries.

• Strategic transformation included divesting non-core businesses (ACT Genomics, Europa, Insighta) to concentrate resources on IM8 and simplify operations.

• IM8's product portfolio includes Daily Ultimate Essentials Pro, Daily Ultimate Longevity, and the Beckham Stack, all manufactured in FDA-registered US facilities and independently tested.

• Brand partnerships with high-profile athletes such as David Beckham, Aryna Sabalenka, and Ollie Bearman enhance global reach and credibility.

Financial performance and metrics

• Achieved $120 million in annualized recurring revenue for IM8 within twelve months of launch.

• As of March 1, 2026, reported approximately $164 million in total adjusted liquidity and zero debt.

• Completed divestitures generated significant non-dilutive capital, including $46 million from ACT Genomics and $70 million from Insighta.

• October 2025 equity offering raised $44 million in gross proceeds to support global expansion.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling shareholders; may receive proceeds from exercise of Exchange Warrants if exercised for cash.

• Proceeds from recent divestitures and equity offerings are allocated to support IM8's global expansion and share repurchase program.

• Authorized a 12-month share repurchase program of up to $40 million in March 2026.